Idiopathic Inflammatory Myositis Epidemiology Summary

• The prevalent cases of Idiopathic Inflammatory Myositis in the 7MM were 198,000 in 2025, rising at a CAGR of 1.1% during the study period; these are expected to by 2036. This growth is primarily driven by population aging, improved disease recognition, greater diagnostic awareness, and enhanced access to specialist care, along with wider use of myositis-specific autoantibody testing and improved classification of inflammatory myopathies.
• Among the 7MM, the US comprised ~50% of the total 7MM prevalent cases of Idiopathic Inflammatory Myositis in 2025; these cases are expected to increase at a CAGR of approximately 1.4% throughout the forecast period.
• In the US, dermatomyositis type was found to be more prevalent that is ~45,300 cases followed by polymyositis (33,800 cases) in 2025 that is expected to increase by 2036.
• Idiopathic Inflammatory Myositis is a heterogeneous autoimmune disease with prevalence varying substantially by subtype, age, and gender. Dermatomyositis and polymyositis contribute substantially to the overall prevalent pool, while IBM is strongly associated with older age, resulting in a greater contribution from elderly populations.
• The Idiopathic Inflammatory Myositis burden increases with advancing age, particularly among individuals aged ≥65 years, driven in part by the increasing occurrence of IBM. Younger populations remain clinically relevant through juvenile and adult-onset dermatomyositis and other inflammatory myopathies.
• Females account for a larger proportion of Idiopathic Inflammatory Myositis cases than males, largely reflecting the female predominance observed in dermatomyositis and polymyositis. However, this pattern varies by subtype, with IBM showing a comparatively greater male representation.
• Among EU4, Germany accounted for the largest number of diagnosed prevalent cases, whereas Spain had the lowest number of cases in 2025.

Idiopathic Inflammatory Myositis (Idiopathic Inflammatory Myositis) Epidemiology Forecast in the 7MM

• 2025 Prevalent Cases of Idiopathic Inflammatory Myositis: ~ 198,000
• 2036 Prevalent Cases of Idiopathic Inflammatory Myositis: ~ 22X,XXX
• Idiopathic Inflammatory Myositis Growth Rate (2026–2036): 1.1% CAGR

DelveInsight's ‘Idiopathic Inflammatory Myositis Epidemiology Forecast – 2036’ report delivers an in-depth understanding of the Idiopathic Inflammatory Myositis, historical and forecasted epidemiology, in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

Idiopathic Inflammatory Myositis Understanding and Diagnosis Algorithm

Idiopathic Inflammatory Myositis (Idiopathic Inflammatory Myositis) Overview and Diagnosis

Idiopathic Inflammatory Myositis is a heterogeneous group of systemic autoimmune disorders characterized primarily by muscle inflammation, weakness, and varying degrees of extramuscular involvement. The major subtypes include dermatomyositis, polymyositis, inclusion body myositis, immune-mediated necrotizing myopathy, and antisynthetase syndrome. Clinical manifestations may include proximal muscle weakness, dysphagia, respiratory involvement, ILD, and characteristic cutaneous features, particularly in dermatomyositis. Disease presentation and progression vary considerably across subtypes, and patients may experience persistent, relapsing, or refractory disease.

Further details are provided in the report...

Idiopathic Inflammatory Myositis Diagnosis

Diagnosis of Idiopathic Inflammatory Myositis requires an integrated assessment of clinical presentation, muscle enzymes, autoantibodies, imaging, and histopathology, as no single diagnostic test is sufficient across all subtypes. Serum creatine kinase (CK), aldolase, AST, and ALT can indicate muscle injury, while myositis-specific and myositis-associated autoantibodies help define clinical phenotypes and identify risks such as interstitial lung disease or characteristic skin manifestations. Electromyography (EMG) and muscle MRI can provide evidence of active muscle inflammation and guide biopsy sites, while muscle or skin biopsy may be used when the diagnosis remains uncertain. Diagnosis is particularly challenging in inclusion body myositis and seronegative disease, where clinical features and complementary investigations are important for distinguishing Idiopathic Inflammatory Myositis from other neuromuscular disorders.

Further details are provided in the report...

Idiopathic Inflammatory Myositis Epidemiology

Key Findings from Idiopathic Inflammatory Myositis Epidemiological Analysis and Forecast

• The total number of prevalent cases of Idiopathic Inflammatory Myositis in the 7MM ranges from approximately 198,000 cases in 2025.
• Among the gender-specific contribution, females had the highest occurrence of cases from ~70% in 2025 in the US.
• The total number of diagnosed prevalent cases of polymyositis in EU4 and the UK was 29,900 in 2025. Similarly, the number of diagnosed prevalent cases of dermatomyositis was 29,300 in 2025, whereas the number of diagnosed prevalent cases of IBM was 8,000 in 2025.
• In 2025, In EU4 and the UK, Spain and the UK had the highest number for diagnosed prevalent cases of dermatomyositis followed by polymyositis and IBM, whereas Germany, France and Italy had the highest number for diagnosed prevalent cases of polymyositis followed by dermatomyositis and IBM.
• In Japan, total number of diagnosed prevalent cases was found in patients aged 65 years and above (55%), followed by 45–64 years (32%).

Scope of the Inflammatory Myositis Epidemiology Report

• The report covers a segment of a descriptive overview of Idiopathic Inflammatory Myositis, explaining their causes, signs and symptoms, and pathogenesis.
• Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of the diagnosis rate, and disease progression.

Inflammatory Myositis Epidemiology Report Insights

• Idiopathic Inflammatory Myositis (Idiopathic Inflammatory Myositis) Patient Population Forecast

Inflammatory Myositis Epidemiology Report Key Strengths

• Epidemiology‑based (Epi‑based) Bottom‑up Forecasting
• 11-year Forecast
• Idiopathic Inflammatory Myositis Patient Burden Trends (by geography)

Discover comprehensive insights into the Idiopathic Inflammatory Myositis market forecast, including epidemiology, emerging therapies, and market forecasts through 2036.

FAQs

• What are the disease risks, burdens, and unmet needs of Idiopathic Inflammatory Myositis? What will be the growth opportunities across the 7MM concerning the patient population with Idiopathic Inflammatory Myositis?
• What is the historical and forecasted Idiopathic Inflammatory Myositis  patient pool in the US, EU4 (Germany, France, Italy, and Spain), the UK, and Japan?

Reasons to Buy Idiopathic Inflammatory Myositis Epidemiology Report:

• Insights on patient burden/disease prevalence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
• To understand key opinion leaders’ perspectives around the diagnostic challenges to overcome barriers in the future.
• Detailed insights on various factors hampering disease diagnosis and other existing diagnostic challenges.